BACKGROUND: A study was undertaken to evaluate the local and systemic inflammatory response associated with pulmonary complications in immunocompromised patients and potential implications regarding severity and prognosis. METHODS: Levels of different inflammatory mediators were measured in the bronchoalveolar lavage (BAL) fluid and serum on days 1 and 4 after the identification of the pulmonary complication in 127 patients with different immunosuppressive conditions. RESULTS: Pulmonary complications were characterised by a high percentage of neutrophils and increased levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8 and IL-10 in the BAL fluid and high serum levels of TNF-alpha, IL-6, and plasma C-reactive protein (CRP). The inflammatory response was similar in the different groups of immunocompromised patients evaluated. The levels of proinflammatory cytokines were higher in patients with pulmonary infections, particularly those of bacterial aetiology. Patients with a more severe pulmonary infection had a more intense local and systemic inflammatory response. A BAL fluid IL-6 level of >40 pg/ml was an independent predictor of mortality (OR 4.65, 95% CI 1.3 to 16.1), together with a need for mechanical ventilation (OR 13.5, 95% CI 3.2 to 57.3). Patients who died had persistently high levels of CRP on day 4. CONCLUSIONS: The evaluation of the inflammatory response, particularly the determination of IL-6 levels in the BAL fluid and CRP in the serum, may be useful for deciding the appropriate management of pulmonary complications in immunocompromised patients.
BACKGROUND: A study was undertaken to evaluate the local and systemic inflammatory response associated with pulmonary complications in immunocompromised patients and potential implications regarding severity and prognosis. METHODS: Levels of different inflammatory mediators were measured in the bronchoalveolar lavage (BAL) fluid and serum on days 1 and 4 after the identification of the pulmonary complication in 127 patients with different immunosuppressive conditions. RESULTS:Pulmonary complications were characterised by a high percentage of neutrophils and increased levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8 and IL-10 in the BAL fluid and high serum levels of TNF-alpha, IL-6, and plasma C-reactive protein (CRP). The inflammatory response was similar in the different groups of immunocompromised patients evaluated. The levels of proinflammatory cytokines were higher in patients with pulmonary infections, particularly those of bacterial aetiology. Patients with a more severe pulmonary infection had a more intense local and systemic inflammatory response. A BAL fluid IL-6 level of >40 pg/ml was an independent predictor of mortality (OR 4.65, 95% CI 1.3 to 16.1), together with a need for mechanical ventilation (OR 13.5, 95% CI 3.2 to 57.3). Patients who died had persistently high levels of CRP on day 4. CONCLUSIONS: The evaluation of the inflammatory response, particularly the determination of IL-6 levels in the BAL fluid and CRP in the serum, may be useful for deciding the appropriate management of pulmonary complications in immunocompromised patients.
Authors: A Rañó; C Agustí; P Jimenez; J Angrill; N Benito; C Danés; J González; M Rovira; T Pumarola; A Moreno; A Torres Journal: Thorax Date: 2001-05 Impact factor: 9.139
Authors: C K Min; W Y Lee; D J Min; D G Lee; Y J Kim; Y H Park; H J Kim; S Lee; D W Kim; J W Lee; W S Min; C C Kim Journal: Bone Marrow Transplant Date: 2001-11 Impact factor: 5.483
Authors: J Angrill; C Agustí; R De Celis; X Filella; A Rañó; M Elena; J P De La Bellacasa; A Xaubet; A Torres Journal: Am J Respir Crit Care Med Date: 2001-11-01 Impact factor: 21.405
Authors: M J Bonten; A H Froon; C A Gaillard; J W Greve; P W de Leeuw; M Drent; E E Stobberingh; W A Buurman Journal: Am J Respir Crit Care Med Date: 1997-10 Impact factor: 21.405
Authors: T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger Journal: Am J Respir Crit Care Med Date: 1995-12 Impact factor: 21.405
Authors: D Viasus; C Gudiol; N Fernández-Sabé; I Cabello; C Garcia-Vidal; M Cisnal; R Duarte; M Antonio; J Carratalà Journal: Eur J Clin Microbiol Infect Dis Date: 2010-09-12 Impact factor: 3.267
Authors: Scott E Evans; Brenton L Scott; Cecilia G Clement; Derek T Larson; Dimitrios Kontoyiannis; Russell E Lewis; P Rocco Lasala; Jennifer Pawlik; Johnny W Peterson; Ashok K Chopra; Gary Klimpel; Gabriela Bowden; Magnus Höök; Yi Xu; Michael J Tuvim; Burton F Dickey Journal: Am J Respir Cell Mol Biol Date: 2009-03-27 Impact factor: 6.914
Authors: J O Cleaver; D You; D R Michaud; F A Guzmán Pruneda; M M Leiva Juarez; J Zhang; P M Weill; R Adachi; L Gong; S J Moghaddam; M E Poynter; M J Tuvim; S E Evans Journal: Mucosal Immunol Date: 2013-05-01 Impact factor: 7.313
Authors: Miguel M Leiva-Juárez; Hayden H Ware; Vikram V Kulkarni; Patrick A Zweidler-McKay; Michael J Tuvim; Scott E Evans Journal: Blood Date: 2016-06-17 Impact factor: 22.113
Authors: C M Lucena; A Torres; M Rovira; M A Marcos; J P de la Bellacasa; M Sánchez; R Domingo; A Gabarrus; J Mensa; C Agustí Journal: Bone Marrow Transplant Date: 2014-07-21 Impact factor: 5.483
Authors: C M Lucena; M Rovira; A Gabarrús; X Filella; C Martínez; R Domingo; A Torres; C Agustí Journal: Bone Marrow Transplant Date: 2016-10-31 Impact factor: 5.483
Authors: Outi E Päiväniemi; Paula K Maasilta; Tiina L S Vainikka; Hanni S Alho; Pekka J Karhunen; Ulla-Stina Salminen Journal: Mediators Inflamm Date: 2009-05-26 Impact factor: 4.711